drugset / Trial / NCT04397003
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Phase 2
Active not recruiting
6 enrolled
Washington University School of Medicine
AstraZeneca · collabGateway for Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that a personalized neoantigen vaccine combined with durvalumab will improve the progression free survival of patients with extensive state small cell lung cancer (ES-SCLC).
Timeline
- Start
- 2022-03-30
- Primary completion
- 2027-09-30
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Neoantigen DNA vaccine | Vaccine | — | Intramuscular |